Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 1:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 33,591 matching trials from the live ClinicalTrials.gov search.
Conditions
Hepatic Disease, Renal Disease
Interventions
Kronos Electrocautery Device
Device
Lead sponsor
Single Pass Inc
Industry
Eligibility
18 Years to 100 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Long Beach, California
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Transauricular Vagus Nerve Stimulation in Children

NCT06168071
Conditions
Hypoxia-Ischemia, Brain
Interventions
taVNS
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
7 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Non-Small Cell Lung Cancer
Interventions
M1774, Cemiplimab
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Santa Monica, California • Pittsburgh, Pennsylvania • Knoxville, Tennessee + 2 more
Conditions
Hepatitis C
Interventions
VCH-222 or matching placebo, peginterferon alfa-2a, ribavirin
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Marietta, Georgia • Detroit, Michigan • Dallas, Texas + 1 more
Conditions
Dengue
Interventions
Emetine Hydrochloride 6mg, Placebo, Emetine Hydrochloride 12mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
NGM282, Placebo
Biological · Other
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
17
States / cities
Chandler, Arizona • Tucson, Arizona • Los Angeles, California + 13 more
Conditions
Familial Mediterranean Fever
Interventions
colchicine sprinkle capsules
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
2 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Primary Biliary Cirrhosis
Interventions
LUM001
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
13
States / cities
La Jolla, California • Sacramento, California • Miami, Florida + 10 more
Completed Phase 2 Interventional Results available

A Study of JNJ-61393215 in the Treatment of Depression

NCT04080752
Conditions
Major Depressive Disorder With Anxious Distress
Interventions
JNJ-61393215, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Garden Grove, California • Alpharetta, Georgia • Atlanta, Georgia + 6 more
Conditions
Autosomal Recessive Polycystic Kidney (ARPKD)
Interventions
Tolvaptan Suspension, Tolvaptan Tablets
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
28 Days to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 9 more
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Lebrikizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 80 Years
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
19
States / cities
Birmingham, Alabama • Northridge, California • Palm Springs, California + 15 more
Completed Phase 3 Interventional Results available

Treatment of Erectile Dysfunction I

NCT01037244
Conditions
Erectile Dysfunction
Interventions
Udenafil, Placebo
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
19 Years and older · Male only
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
36
States / cities
Birmingham, Alabama • Homewood, Alabama • Mesa, Arizona + 32 more
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
TKI258
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Mobile, Alabama • Alhambra, California • Santa Maria, California + 12 more
Conditions
Breast Augmentation
Interventions
Exparel Injectable Product, Bupivacaine Hydrochloride
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bellaire, Texas
Completed Phase 1Phase 2 Interventional Results available

TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals

NCT05275998
Conditions
HIV-1-infection
Interventions
TMB-365/TMB-380
Drug
Lead sponsor
TaiMed Biologics Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
San Francisco, California • Fort Lauderdale, Florida • Ft. Pierce, Florida + 3 more
Conditions
Stroke, Ischemic, Pain, Postoperative, Substance Abuse, Subarachnoid Hemorrhage
Interventions
Placebo, NP10679
Drug
Lead sponsor
Neurop Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma, Ovarian Cancer, Anogenital Cancers, HPV - Anogenital Human Papilloma Virus Infection, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Malignancy, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Verrucous Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
Interventions
TSC-204-A0201, TSC-204-C0702, TSC-200-A0201, TSC-204-A0201 + TSC-204-C0702, TSC-204-A0201 + TSC-200-A0201, TSC-204-C0702 + TSC-200-A0201, TSC-204-A0201 + TSC-203-A0201, TSC-204-C0702 + TSC-203-A0201, TSC-200-A0201 + TSC-203-A0201, TSC-203-A0201, TSC-204-A0101, TSC-201-B0702, TSC-204-A0201 + TSC-204-A0101, TSC-204-A0201 + TSC-201-B0702, TSC-204-C0702 + TSC-204-A0101, TSC-204-C0702 + TSC-201-B0702, TSC-200-A0201 + TSC-204-A0101, TSC-200-A0201 + TSC-201-B0702, TSC-203-A0201 + TSC-204-A0101, TSC-203-A0201 + TSC-201-B0702, TSC-202-A0201, TSC-204-A0201 + TSC-202-A0201, TSC-204-C0702 + TSC-202-A0201, TSC-200-A0201 + TSC-202-A0201, TSC-203-A0201 + TSC-202-A0201, TSC-204-A0101 + TSC-202-A0201, TSC-201-B0702 + TSC-202-A0201
Biological
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
21
States / cities
Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more
Conditions
Type 2 Diabetes Mellitus
Interventions
LY3053102, Exenatide ER, Placebo, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Orange, California • Miami, Florida • Orlando, Florida + 2 more
Conditions
Leptomeningeal Metastasis
Interventions
186RNL
Drug
Lead sponsor
Cerenome
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Hepatitis C
Interventions
SOF, VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
40
States / cities
Long Beach, California • Los Angeles, California • Pasadena, California + 37 more
Conditions
Acute Myeloid Leukemia (AML), Minimal Residual Disease
Interventions
Azacitidine, Avelumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Von Willebrand Disease
Interventions
Wilate
Drug
Lead sponsor
Octapharma
Industry
Eligibility
Up to 5 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New Orleans, Louisiana
Terminated Phase 2 Interventional Results available

Pramipexole ER vs. Placebo in Fibromyalgia

NCT00689052
Conditions
Fibromyalgia
Interventions
pramipexole ER, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 39 more
Conditions
COPD
Interventions
OnabotulinumtoxinA, Placebo
Drug · Other
Lead sponsor
RMW Testing
Industry
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Webster, Texas